JP2019534867A - カンナビノイド受容体結合リガンドを含む組成物 - Google Patents

カンナビノイド受容体結合リガンドを含む組成物 Download PDF

Info

Publication number
JP2019534867A
JP2019534867A JP2019516407A JP2019516407A JP2019534867A JP 2019534867 A JP2019534867 A JP 2019534867A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019534867 A JP2019534867 A JP 2019534867A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
thc
composition according
receptor binding
cannabinoid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019516407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534867A5 (enExample
Inventor
ベルンハルト グンター，
ベルンハルト グンター，
フランク ルッシャー，
フランク ルッシャー，
ソンニャ クレッサー，
ソンニャ クレッサー，
フィリップ スティーヴェン
フィリップ スティーヴェン
Original Assignee
ノバリック ゲーエムベーハー
ノバリック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバリック ゲーエムベーハー, ノバリック ゲーエムベーハー filed Critical ノバリック ゲーエムベーハー
Publication of JP2019534867A publication Critical patent/JP2019534867A/ja
Publication of JP2019534867A5 publication Critical patent/JP2019534867A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019516407A 2016-09-28 2017-09-27 カンナビノイド受容体結合リガンドを含む組成物 Pending JP2019534867A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16191194.6 2016-09-28
EP16191194 2016-09-28
EP17168172 2017-04-26
EP17168172.9 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (2)

Publication Number Publication Date
JP2019534867A true JP2019534867A (ja) 2019-12-05
JP2019534867A5 JP2019534867A5 (enExample) 2020-04-09

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516407A Pending JP2019534867A (ja) 2016-09-28 2017-09-27 カンナビノイド受容体結合リガンドを含む組成物

Country Status (10)

Country Link
US (1) US20190343793A1 (enExample)
EP (2) EP3698785A1 (enExample)
JP (1) JP2019534867A (enExample)
KR (1) KR20190060787A (enExample)
CN (1) CN109803650A (enExample)
AU (1) AU2017333420A1 (enExample)
BR (1) BR112019006194A2 (enExample)
CA (1) CA3036313A1 (enExample)
MX (1) MX2019003544A (enExample)
WO (1) WO2018060282A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073541A (ja) * 2016-12-27 2021-05-13 フェイスブック・テクノロジーズ・リミテッド・ライアビリティ・カンパニーＦａｃｅｂｏｏｋ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｌｌｃ 触覚デバイスの大規模集積化
JP2023543925A (ja) * 2020-10-05 2023-10-18 マックス バイオロジー カンパニー リミテッド カンナビノイド含有組成物及び疾患の処置及び予防のための使用
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
JP6039152B2 (ja) 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
BR112015004997B1 (pt) 2012-09-12 2022-09-13 Novaliq Gmbh Composições oftálmicas contendo misturas de alcanos semifluorados
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
WO2017055453A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
KR102295739B1 (ko) 2016-05-03 2021-08-30 뉴마 레스퍼러토리 인코포레이티드 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
EP3515420B1 (en) 2016-09-22 2023-11-08 Novaliq GmbH Pharmaceutical compositions for use in the therapy of blepharitis
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
CN110678207B (zh) 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
EP3687496A1 (en) 2017-09-27 2020-08-05 Novaliq GmbH Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11738158B2 (en) 2017-10-04 2023-08-29 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device and methods of use
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
AU2020216470B2 (en) * 2019-02-01 2023-05-04 Alcon Inc. Compounds, compositions and methods for treatment of myopia
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
MX2022002667A (es) 2019-09-06 2022-04-07 Novaliq Gmbh Composicion oftalmica para el tratamiento de uveitis.
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
EP4288151A4 (en) 2021-02-03 2025-01-01 ADS Therapeutics LLC Topical ophthalmological compositions
KR20240037245A (ko) 2021-06-22 2024-03-21 뉴마 레스퍼러토리 인코포레이티드 푸시 이젝션에 의한 액적 전달 장치
WO2023064477A1 (en) * 2021-10-13 2023-04-20 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
KR20250038748A (ko) 2022-07-18 2025-03-19 뉴마 레스퍼러토리 인코포레이티드 작은 스텝 크기 및 고해상도 에어로졸 생성 시스템 및 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511157A (ja) * 1995-09-29 2000-08-29 マイネルト，ハッソ セミフルオロアルカン及びその使用
JP2013513586A (ja) * 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物
JP2013540140A (ja) * 2010-10-20 2013-10-31 ノバリック ゲーエムベーハー 有効成分の送達のための液体医薬組成物
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2016109531A1 (en) * 2014-12-30 2016-07-07 Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659775A1 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
ES2622582T3 (es) 2008-10-31 2017-07-06 University Of Mississippi Proceso para la preparación de ésteres de delta-9-THC-aminoácido
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
JP6039152B2 (ja) * 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
BR112015004997B1 (pt) * 2012-09-12 2022-09-13 Novaliq Gmbh Composições oftálmicas contendo misturas de alcanos semifluorados
CN106061490A (zh) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511157A (ja) * 1995-09-29 2000-08-29 マイネルト，ハッソ セミフルオロアルカン及びその使用
JP2013513586A (ja) * 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物
JP2013540140A (ja) * 2010-10-20 2013-10-31 ノバリック ゲーエムベーハー 有効成分の送達のための液体医薬組成物
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2016109531A1 (en) * 2014-12-30 2016-07-07 Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AM J DRUG DELIV, vol. 2, no. 4, JPN6021023811, 2004, pages 229 - 240, ISSN: 0004827481 *
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 88, JPN6021023813, 2014, pages 123 - 128, ISSN: 0004827482 *
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 57, JPN6021023814, 2016, pages 417, ISSN: 0004827483 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073541A (ja) * 2016-12-27 2021-05-13 フェイスブック・テクノロジーズ・リミテッド・ライアビリティ・カンパニーＦａｃｅｂｏｏｋ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｌｌｃ 触覚デバイスの大規模集積化
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤
JP2023543925A (ja) * 2020-10-05 2023-10-18 マックス バイオロジー カンパニー リミテッド カンナビノイド含有組成物及び疾患の処置及び予防のための使用

Also Published As

Publication number Publication date
CA3036313A1 (en) 2018-04-05
EP3698785A1 (en) 2020-08-26
BR112019006194A2 (pt) 2019-06-18
MX2019003544A (es) 2019-09-19
KR20190060787A (ko) 2019-06-03
US20190343793A1 (en) 2019-11-14
EP3518921B1 (en) 2021-08-11
AU2017333420A1 (en) 2019-04-04
CN109803650A (zh) 2019-05-24
WO2018060282A1 (en) 2018-04-05
EP3518921A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
EP3518921B1 (en) Compositions comprising a cannabinoid receptor binding ligand
JP6397472B2 (ja) ドライアイ症候群の治療のための医薬組成物
US9937225B2 (en) Topical formulations and uses thereof
US20200009137A1 (en) Topical formulations and uses thereof
WO2017152129A2 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
HK40036791A (en) Compositions comprising a cannabinoid receptor binding ligand
HK40008248A (en) Compositions comprising a cannabinoid receptor binding ligand

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220719